[go: up one dir, main page]

ZA952375B - Isolated tumor rejection antigen precursor mage-2 derived peptides and uses thereof - Google Patents

Isolated tumor rejection antigen precursor mage-2 derived peptides and uses thereof

Info

Publication number
ZA952375B
ZA952375B ZA952375A ZA952375A ZA952375B ZA 952375 B ZA952375 B ZA 952375B ZA 952375 A ZA952375 A ZA 952375A ZA 952375 A ZA952375 A ZA 952375A ZA 952375 B ZA952375 B ZA 952375B
Authority
ZA
South Africa
Prior art keywords
tumor rejection
rejection antigen
antigen precursor
derived peptides
complexes
Prior art date
Application number
ZA952375A
Other languages
English (en)
Inventor
Cornelis J M Melief
M W Visseren
W M Kast
Pierre Van Der Bruggen
Thierry Boon-Falleur
Original Assignee
Ludwig Inst Cancer Res
Univ Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Univ Leiden filed Critical Ludwig Inst Cancer Res
Priority to TW084103311A priority Critical patent/TW419483B/zh
Publication of ZA952375B publication Critical patent/ZA952375B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA952375A 1994-03-24 1995-03-23 Isolated tumor rejection antigen precursor mage-2 derived peptides and uses thereof ZA952375B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW084103311A TW419483B (en) 1994-03-24 1995-04-07 Isolated tumor rejection antigen precursor mage-2 derived peptides, and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/217,188 US5554724A (en) 1994-03-24 1994-03-24 Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof

Publications (1)

Publication Number Publication Date
ZA952375B true ZA952375B (en) 1995-12-15

Family

ID=22810016

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA952375A ZA952375B (en) 1994-03-24 1995-03-23 Isolated tumor rejection antigen precursor mage-2 derived peptides and uses thereof

Country Status (17)

Country Link
US (3) US5554724A (xx)
EP (1) EP0810870B1 (xx)
JP (1) JP3360137B2 (xx)
CN (1) CN1149257A (xx)
AT (1) ATE201214T1 (xx)
AU (1) AU682597B2 (xx)
CA (1) CA2186006A1 (xx)
DE (1) DE69520959T2 (xx)
DK (1) DK0810870T3 (xx)
ES (1) ES2158943T3 (xx)
FI (1) FI963780A (xx)
GR (1) GR3036320T3 (xx)
NO (1) NO963918L (xx)
NZ (2) NZ329695A (xx)
PT (1) PT810870E (xx)
WO (1) WO1995025530A1 (xx)
ZA (1) ZA952375B (xx)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
WO1997035035A1 (en) * 1996-03-20 1997-09-25 Charles Nicolette A method for identifying cytotoxic t-cell epitopes
US6087441A (en) * 1997-02-05 2000-07-11 Ludwig Institute For Cancer Research Structurally modified peptides that are resistant to peptidase degradation
US6680191B1 (en) 1997-04-25 2004-01-20 Ludwig Institute For Cancer Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
US6027924A (en) * 1997-04-25 2000-02-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
ATE377022T1 (de) 1997-06-23 2007-11-15 Ludwig Inst Cancer Res Isolierte decapeptide, die an hla moleküle binden,sowie deren verwendung
US6025470A (en) 1997-06-23 2000-02-15 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
EP1103561B1 (en) * 1998-07-28 2006-04-19 Green Peptide Co., Ltd. Hla-a2 restraint tumor antigen peptide originating in sart-1
GB9826143D0 (en) * 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
ATE391726T1 (de) 1999-10-22 2008-04-15 Sanofi Pasteur Ltd Modifiziertes gp100 und dessen verwendung
DE60124899T2 (de) 2000-05-10 2007-08-16 Sanofi Pasteur Ltd., Toronto Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
WO2003085087A2 (en) 2002-04-09 2003-10-16 Aventis Pasteur, Limited Modified cea nucleic acid and expression vectors
EP2314712B1 (en) * 2001-11-07 2014-01-08 Mannkind Corporation Expression vectors encoding epitopes of antigens and methods for their design
WO2004015390A2 (en) * 2002-08-09 2004-02-19 Applera Corporation Lung cancer target proteins and use thereof
AU2003278036B2 (en) * 2002-10-22 2009-12-10 Aventis Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
CA2522812C (en) * 2003-04-18 2012-08-21 Idm Pharma, Inc. Hla-a2 tumor associated antigen peptides and compositions
KR101162970B1 (ko) * 2003-10-08 2012-07-12 테리온 바이오로직스, 인크. 변형된 ｃｅａ/ｂ7 벡터
US7338670B2 (en) 2005-04-14 2008-03-04 Duke University Use of an agent that restores tissue perfusion and oxygenation
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
CA2774636C (en) 2009-09-25 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use
BR112013023027A2 (pt) 2011-03-07 2016-08-16 Creative Neail Design Inc composições e métodos para esmaltes de unha curáveis por uv
WO2013137953A1 (en) 2012-03-15 2013-09-19 Exxonmobil Chemical Patents Inc. Oxygen tailoring of polyethylene
FR3008099B1 (fr) 2013-07-05 2020-08-07 Commissariat Energie Atomique Peptides immunogenes de l'antigene tumoral cycline b1
FR3090319A1 (fr) 2018-12-21 2020-06-26 Commissariat A L'energie Atomique Et Aux Energies Alternatives Melanges d’epitopes t cd8+ immunogenes de la cycline b1
CN116731155B (zh) * 2022-09-21 2024-03-22 新景智源生物科技(苏州)有限公司 人乳头瘤病毒特异性t细胞受体、表达其的细胞和其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
CA2141960A1 (en) * 1992-08-07 1994-02-17 Ralph T. Kubo Hla binding peptides and their uses
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US5462871A (en) * 1992-08-31 1995-10-31 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode MAGE derived nonapeptides
US5487974A (en) * 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
CA2157510A1 (en) * 1993-03-05 1994-09-15 Howard M. Grey Hla-a2.1 binding peptides and their uses
US5554506A (en) * 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof

Also Published As

Publication number Publication date
NZ283561A (en) 1998-04-27
JP3360137B2 (ja) 2002-12-24
DE69520959D1 (de) 2001-06-21
DK0810870T3 (da) 2001-07-23
EP0810870A4 (en) 1998-11-25
US6147187A (en) 2000-11-14
WO1995025530A1 (en) 1995-09-28
FI963780A0 (fi) 1996-09-23
ATE201214T1 (de) 2001-06-15
ES2158943T3 (es) 2001-09-16
GR3036320T3 (en) 2001-11-30
FI963780A (fi) 1996-09-23
AU2189395A (en) 1995-10-09
US6063900A (en) 2000-05-16
JPH10502329A (ja) 1998-03-03
CA2186006A1 (en) 1995-09-28
NZ329695A (en) 2000-05-26
DE69520959T2 (de) 2002-03-28
NO963918D0 (no) 1996-09-19
AU682597B2 (en) 1997-10-09
NO963918L (no) 1996-11-20
EP0810870B1 (en) 2001-05-16
CN1149257A (zh) 1997-05-07
EP0810870A1 (en) 1997-12-10
US5554724A (en) 1996-09-10
PT810870E (pt) 2001-09-28

Similar Documents

Publication Publication Date Title
GR3036320T3 (en) Isolated tumor rejection antigen precursor mage-2 derived peptides, and uses thereof
den Haan et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen
CA2186004A1 (en) Isolated peptides derived from mage tumor rejection antigen precursors which complex with hla-a2 molecules
GR3031811T3 (en) Isolated, mage-3 derived peptides which complex with hla-a2 molecules and uses thereof
ATE447585T1 (de) Antigener komplex, der ein immunstimulierendes peptid enthält, cd4 und chemokinrezeptor-domäne zur behandlung von hiv und immunerkrankungen
NO175944C (no) Monoklonale antistoffer for anvendelse til in vitro påvisning av tumorassosiert mucinantigen, og hybridomcellelinjer som produserer disse
BR9914116A (pt) Composições e métodos para imunoterapia especìfica de wt1
CA2045552A1 (en) Cancer related haptoglobin
CA2036814A1 (en) Monoclonal antibodies against tumor-associated antigens, a process for the preparation thereof and the use thereof
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164
GB9826143D0 (en) Tumour rejection antigens
NZ331398A (en) Tumor rejection antigens presented by hla-b44 molecules, and uses thereof
DE69328114D1 (en) Peptide als diagnose- und therapiemittel für spondyloarthropathien
NO965087L (no) Isolert nukleinsyremolekyl som koder for en tumorrejeksjonsantigenforlöper, og anvendelse derav
WO2004011483A3 (en) Isolated, ssx-2 and ssx-2 related peptides useful as hla binders and ctl epitopes, and uses thereof
NZ509417A (en) Novel peptides for use in immunotherapy of autoimmune diseases
HK1016482A1 (en) Tumor rejection antigens presented by hla-b44 molecules, and uses thereof.
Belle et al. Identification of HLA‐A2 restricted T‐cell epitopes within the conserved region of the immunoglobulin G heavy‐chain in patients with multiple myeloma
Chen et al. Comparison of the binding parameters to melanoma cells of antihuman high molecular weight-melanoma associated antigen (HMW-MAA) monoclonal antibodies (mAb) and syngeneic anti-anti-idiotypic (anti-anti-id) mAb
Myeloma-Reactive et al. Targeting Positive Regulatory Domain
Townsend et al. Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
GR890100333A (en) Antihuman antigen antibodies